NIH VideoCast - A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug Repurposing

Skip Navigation

A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug Repurposing

0 seconds of 0 secondsVolume 90%

00:25

00:00

00:00

1,072 Views

Air date:	Wednesday, June 24, 2020, 3:00:00 PM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 1,072 (641 Live, 431 On-demand)
Category:	COVID-19
Runtime:	00:55:49
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	NIH COVID-19 SIG Lecture Series Efforts to develop antiviral drugs versus COVID-19 or vaccines for its prevention have been hampered by limited knowledge of the molecular details of SARS-CoV-2, the virus that causes COVID-19. This webinar will describe Nevan Krogan's efforts to address this challenge. He and his lab expressed 26 of the 29 SARS-CoV-2 proteins in human cells and are using affinity–purification mass spectrometry to identify the human proteins physically associated with each. Among 332 high–confidence SARS-CoV-2-human protein–protein interactions, Krogan's lab has identified 66 druggable human proteins or host factors targeted by 69 compounds (29 FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical compounds). Within a subset of these, Krogan's lab has used several viral assays to identify two sets of pharmacological agents that displayed antiviral activity.

NLM Title:	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing / Nevan Krogan.
Author:	Krogan, Nevan J. National Institutes of Health (U.S.). COVID-19 Scientific Interest Group,
Publisher:
Abstract:	(CIT): NIH COVID-19 SIG Lecture Series. Efforts to develop antiviral drugs versus COVID-19 or vaccines for its prevention have been hampered by limited knowledge of the molecular details of SARS-CoV-2, the virus that causes COVID-19. This webinar will describe Nevan Krogan's efforts to address this challenge. He and his lab expressed 26 of the 29 SARS-CoV-2 proteins in human cells and are using affinity-purification mass spectrometry to identify the human proteins physically associated with each. Among 332 high-confidence SARS-CoV-2-human protein-protein interactions, Krogan's lab has identified 66 druggable human proteins or host factors targeted by 69 compounds (29 FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical compounds). Within a subset of these, Krogan's lab has used several viral assays to identify two sets of pharmacological agents that displayed antiviral activity.
Subjects:	Betacoronavirus--drug effects Drug Delivery Systems Drug Repositioning Protein Biosynthesis--drug effects Protein Interaction Maps Viral Nonstructural Proteins--drug effects
Publication Types:	Lecture Webcast

NLM Classification:	QW 168.5.C8
NLM ID:	101769638
CIT Live ID:	37828
Permanent link:	https://videocast.nih.gov/watch=37828

Related Videos...